This article is more than 5 years old. Information may no longer be current.
Foundation Medicine announces participation in NCI-MATCH trial
Click Here to Manage Email Alerts
Foundation Medicine, NCI and ECOG-ACRIN Cancer Research Group entered a collaboration to evaluate the benefit of genomically guided treatments targeting specific alterations within a patient’s tumor, regardless of cancer type.
The phase 2 NCI-MATCH Study is designed to determine the effectiveness of treatment that is directed by genomic profiling in patients with solid tumors, lymphomas, or myelomas that have progressed following all standard treatments or in patients with rare cancer types for which there is no standard treatment.
The FoundationOne and FoundationOne Heme assays comprehensively interrogate hundreds of cancer-related genes in solid tumors, hematologic malignancies and advanced sarcomas to identify genomic alterations that may help match a patient with a therapy in conjunction with their respective genomic alterations.
“The NCI-MATCH trial is vital to learning more about the genomic basis of cancer biology and the best ways to improve cancer treatment for each individual patient,” Vincent Miller, MD, chief medical officer at Foundation Medicine, said in a press release. “We believe this innovative trial design leveraging genomics to inform potential treatment modalities will become the standard for oncology clinical studies, particularly to identify signals of effectiveness that can be studied in larger, more definitive trials.”
Foundation Medicine will notify oncologists at the participating clinical sites when the genomic assays reveal findings that may make a patient eligible for one of several NCI-MATCH treatments.
The oncologist may then take this information into consideration when discussing treatment options for their patient.
“We believe our collaboration will help the clinical sites participating in the trial to identify a larger number of patients who may be eligible to enroll for treatment,” Miller said.